Blood drop transforming into healthy skin, contrasted with melanoma landscape, symbolizing NLR's role in predicting melanoma recurrence.

Decoding Melanoma: Can a Simple Blood Test Predict Recurrence?

Elliot Brynn in Health & Wellness December 2025 • 4 min read.

"New research explores how the neutrophil-to-lymphocyte ratio (NLR) can help predict recurrence in stage III melanoma patients, potentially transforming personalized treatment strategies."

Melanoma, a dangerous form of skin cancer, poses a significant threat, with approximately 10,130 lives claimed annually in the United States alone. Melanoma is classified into five stages (0-IV), with Stage III marking the presence of regional metastases. This stage is further divided into subgroups (IIIA, IIIB, IIIC), each presenting distinct survival rates, underscoring the need for precise prognostic tools.

Predicting melanoma recurrence is a critical challenge. Recent research highlights the potential of the Neutrophil-to-Lymphocyte Ratio (NLR), a simple calculation derived from a standard blood test, as a predictive marker. NLR reflects the balance between neutrophils (a type of white blood cell involved in inflammation) and lymphocytes (another type of white blood cell crucial for immune response). An elevated NLR suggests a heightened inflammatory state, which has been linked to poorer outcomes in various cancers.

This article delves into a groundbreaking study investigating the role of NLR in predicting disease-free survival (DFS) among patients with Stage III melanoma. By analyzing a cohort of patients treated at the Huntsman Cancer Institute, University of Utah, researchers uncovered compelling evidence that NLR could serve as a valuable tool in personalizing treatment strategies and improving patient outcomes.

What is Neutrophil-to-Lymphocyte Ratio (NLR)?

Blood drop transforming into healthy skin, contrasted with melanoma landscape, symbolizing NLR's role in predicting melanoma recurrence.

The neutrophil-to-lymphocyte ratio (NLR) is a readily accessible biomarker derived from a routine blood test. It represents the balance between two types of white blood cells: neutrophils and lymphocytes. Neutrophils are the first responders to infection and inflammation, while lymphocytes are crucial for adaptive immunity, targeting specific threats.

NLR is calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. The resulting ratio reflects the relative proportion of these two immune cell populations in the blood. An elevated NLR typically indicates a higher number of neutrophils relative to lymphocytes, suggesting a state of systemic inflammation or immune dysregulation.

Inflammation Marker: Elevated NLR often signals increased inflammation within the body.
Immune Response Indicator: Reflects the balance between pro-inflammatory and anti-inflammatory immune responses.
Accessibility: Easily obtained from routine blood tests, making it a cost-effective and accessible biomarker.
Prognostic Value: Studies have linked NLR to prognosis in various cancers and other diseases.

In the context of cancer, a high NLR has been associated with poorer outcomes, including decreased overall survival and increased risk of recurrence. This suggests that a pro-inflammatory environment may promote tumor growth, metastasis, and resistance to therapy. As such, NLR has emerged as a promising prognostic marker in various malignancies, including melanoma.

The Future of Melanoma Treatment

The study highlights the potential of NLR as a predictive tool for recurrence in stage III melanoma. By identifying patients at higher risk of recurrence, clinicians can tailor treatment strategies, potentially intensifying adjuvant therapy or implementing more frequent monitoring. Further research is needed to validate these findings in larger, prospective studies and to explore the underlying mechanisms linking NLR to melanoma progression. Ultimately, incorporating NLR into clinical decision-making could lead to more personalized and effective treatment approaches, improving outcomes for individuals facing this challenging disease.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is the Neutrophil-to-Lymphocyte Ratio (NLR) and why is it important in the context of melanoma?

The Neutrophil-to-Lymphocyte Ratio (NLR) is a calculation derived from a routine blood test, representing the balance between neutrophils and lymphocytes. Neutrophils are involved in inflammation, while lymphocytes are crucial for immune response. In melanoma, particularly Stage III, a high NLR indicates a heightened inflammatory state, which can be associated with poorer outcomes such as increased risk of recurrence. This makes NLR a valuable biomarker for predicting disease progression and personalizing treatment strategies.

How does the Neutrophil-to-Lymphocyte Ratio (NLR) help predict recurrence in Stage III melanoma patients?

NLR helps predict recurrence in Stage III melanoma by reflecting the body's inflammatory state. An elevated NLR, indicating more neutrophils relative to lymphocytes, suggests a pro-inflammatory environment. This environment may promote tumor growth, metastasis, and resistance to therapy. By assessing NLR, clinicians can identify patients at higher risk of recurrence, enabling them to tailor treatment, such as intensifying adjuvant therapy or increasing monitoring frequency.

What are the implications of having an elevated Neutrophil-to-Lymphocyte Ratio (NLR) for a Stage III melanoma patient?

An elevated Neutrophil-to-Lymphocyte Ratio (NLR) in a Stage III melanoma patient has several implications. It often signifies a heightened inflammatory state, which can be linked to poorer outcomes. This includes a higher risk of melanoma recurrence, decreased overall survival, and potential resistance to treatment. Clinically, it suggests the need for more aggressive treatment approaches, such as intensified adjuvant therapy or more frequent follow-up, to manage the disease effectively.

Why is the Neutrophil-to-Lymphocyte Ratio (NLR) considered a promising tool for personalizing melanoma treatment?

The Neutrophil-to-Lymphocyte Ratio (NLR) is promising for personalizing melanoma treatment because it provides a simple, accessible, and cost-effective way to assess a patient's prognosis. By using NLR, clinicians can identify Stage III melanoma patients at higher risk of recurrence. This allows for tailoring treatment strategies, such as adjusting the intensity of adjuvant therapy or modifying the frequency of patient monitoring. This personalized approach aims to improve patient outcomes and increase the effectiveness of interventions, rather than relying on a one-size-fits-all approach.

Beyond the Neutrophil-to-Lymphocyte Ratio (NLR), what other factors influence the treatment and outcomes of Stage III melanoma?

While the Neutrophil-to-Lymphocyte Ratio (NLR) is a valuable tool, other factors influence the treatment and outcomes of Stage III melanoma. The specific subgroup of Stage III melanoma (IIIA, IIIB, IIIC), which reflects the extent of regional metastases, is crucial. Other factors include the patient's overall health, the characteristics of the melanoma tumor itself (such as its thickness and ulceration), and the specific treatment modalities employed (surgery, immunotherapy, targeted therapy, or radiation). Further research is ongoing to understand the complex interplay of these factors to improve treatment strategies.